RESUMO
Many trials were made to prepare a satisfactory formula for potassium chloride as a sustained release tablet dosage form by employing various retardants [carnauba wax, stearic acid and bees wax] using fusion method for dispersion. It was found that the release of drug is affected by the concentration of total wax contents, by the type of waxy material, and by the ratio of one type of wax to the other when a combination of two waxes were used. The best formula was obtained from combination of carnauba wax and stearic acid as a 20% total wax contents of the tablet weight in a ratio of 1:1. In addition, acrylic resin Eudragit[TM] Ll00 and Eudragit[TM] RS PM were used as a film coating material. More satisfactory results were obtained by coating the tablet for 5 times with Eudragit[TM] Ll00 which has an enteric property. Comparing the dissolution of the prepared tablets with KCL- retard Zyma[R] tablets showed that, the release of drug from the selected formula was more or less similar to that obtained from KCL- retard Zyma[R] tablets at pH 7.6 and 37C. The dissolution rate constants were: K1: 0.5 meq. min-1/2, K2: 0.27 meq. min-1/2 and K1: 0.52 meq. min-1/2, K2: 0.31 meq. min -1/2, for the selected formula and KCL- retard Zyma[R]] tablets, respectively. The results of this study indicate that the selected formula could be used to prepare sustained release tablets of potassium chloride
Assuntos
Preparações de Ação Retardada , Química Farmacêutica , ComprimidosRESUMO
The bioavailability of the formulated enteric coated sustained release potassium chloride tablets was measured from the urinary excretion data of the drug after a single does of 40 meq k+ [5 tablets]. The cumulative excretion data showed that 80% +/- 13.56 of the administered does was excreted within 24 hours. The bioavailability of the formulated tablets was 94.87% relative of the commercially available sugar coated KCL- retard Zyma [R] tablets